• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

2022 SUO Annual Meeting recap: Use of doublet therapy in metastatic prostate cancer varies by location


“This study highlights how treatment remains influenced by where you live,” Diana Magee, MD, MPH, MSc.

In this video, Diana Magee, MD, MPH, MSc, summarizes the 2022 Society of Urologic Oncology Annual Meeting presentation, “Geographic variation in utilization of doublet therapy for metastatic prostate cancer.” Magee is a urologic oncology fellow at Fox Chase Cancer Center in Philadelphia, Pennsylvania.

Related Videos
Michael S. Cookson, MD, MMHC, FACS, answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.